On 10 September, TauRx Therapeutics and BrainMind launched new educational materials on the role of tau in Alzheimer’s disease (AD) at a meeting organised by Alzheimer Europe and attended by 24 of its national member organisations. The illustrations are the result of the peer-reviewed, published science, developed by BrainMind through an educational grant from TauRx, with an aim to explain to doctors and their patients how abnormal tau aggregation affects the brain and how this could be treated.
TauRx’s goal in providing these materials first to Alzheimer Europe and its members, is to help people understand how its lead compound, hydromethylthionine, works and how it might benefit the research participants currently enrolling in its ongoing LUCIDITY clinical trial. The purpose of this study is to determine the safety and efficacy of hydromethylthionine in the treatment of people with Alzheimer's disease. The trial has already started recruitment in France, Italy, Poland, Spain, UK and US. Results are expected to be available by mid-2022.
“People living with Alzheimer’s disease, their families and carers, as well as Alzheimer’s associations are closely following research developments in the hope of better treatment and prevention possibilities. Alzheimer Europe aims to provide easy-to-understand information on ongoing clinical trials and we are therefore very grateful to TauRx for presenting their phase III programme to our members. The educational material and visuals launched at our meeting will be very useful in explaining the important role of tau in the development of Alzheimer’s disease to a non-scientific audience”, said Jean Georges, Executive Director of Alzheimer Europe.